Editorial: Vascular co-option and beyond for cancer biology.
作者信息
Pezzella Francesco, Qian Chao-Nan
机构信息
Nuffield Division of Clinical Laboratory Science-Radcliffe Department of Medicine (NDCLS-RDM) John Radcliffe Hospital, University of Oxford, Oxford, United Kingdom.
Department of Radiation Oncology, Guangzhou Concord Cancer Center, Guangzhou, China.
出版信息
Front Oncol. 2023 Jun 19;13:1227540. doi: 10.3389/fonc.2023.1227540. eCollection 2023.
Abstract
摘要
相似文献
1
Editorial: Vascular co-option and beyond for cancer biology.社论：癌症生物学中的血管共选及其他方面
Front Oncol. 2023 Jun 19;13:1227540. doi: 10.3389/fonc.2023.1227540. eCollection 2023.
2
Vascular Co-Option and Other Alternative Modalities of Growth of Tumor Vasculature in Glioblastoma.胶质母细胞瘤中肿瘤血管生成的血管共选及其他替代模式
Front Oncol. 2022 Mar 30;12:874554. doi: 10.3389/fonc.2022.874554. eCollection 2022.
3
Vessel co-option is common in human lung metastases and mediates resistance to anti-angiogenic therapy in preclinical lung metastasis models.血管共选在人类肺转移中很常见，并在临床前肺转移模型中介导对抗血管生成治疗的耐药性。
J Pathol. 2017 Feb;241(3):362-374. doi: 10.1002/path.4845. Epub 2016 Dec 29.
4
Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?原发性人类肿瘤和转移瘤中的血管生成拟态：抗血管生成治疗的障碍？
Cancer Med. 2013 Aug;2(4):427-36. doi: 10.1002/cam4.105. Epub 2013 Jul 8.
5
Vessel co-option and resistance to anti-angiogenic therapy.血管生成拟态与抗血管生成治疗抵抗。
Angiogenesis. 2020 Feb;23(1):55-74. doi: 10.1007/s10456-019-09698-6. Epub 2019 Dec 21.
6
Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?非小细胞肺癌中的血管生成：血管共选择是维持分支的主干吗？
Oncotarget. 2017 Jun 13;8(24):39795-39804. doi: 10.18632/oncotarget.7794.
7
Different Forms of Tumor Vascularization and Their Clinical Implications Focusing on Vessel Co-option in Colorectal Cancer Liver Metastases.肿瘤血管生成的不同形式及其临床意义——聚焦于结直肠癌肝转移中的血管共选择
Front Cell Dev Biol. 2021 Apr 12;9:612774. doi: 10.3389/fcell.2021.612774. eCollection 2021.
8
Vessel co-option: how tumors obtain blood supply in the absence of sprouting angiogenesis.血管共选：肿瘤在无新生血管生成时如何获得血液供应。
Endothelium. 2002;9(2):83-7. doi: 10.1080/10623320212006.
9
Broad targeting of angiogenesis for cancer prevention and therapy.针对癌症预防和治疗的广泛血管生成靶向作用。
Semin Cancer Biol. 2015 Dec;35 Suppl(Suppl):S224-S243. doi: 10.1016/j.semcancer.2015.01.001. Epub 2015 Jan 16.
10
Differential P-Glycoprotein/CD31 Expression as Markers of Vascular Co-Option in Primary Central Nervous System Tumors.差异表达的P-糖蛋白/CD31作为原发性中枢神经系统肿瘤血管共选的标志物
Diagnostics (Basel). 2022 Dec 10;12(12):3120. doi: 10.3390/diagnostics12123120.
引用本文的文献
1
Vascular co-option in resistance to anti-angiogenic therapy.抗血管生成治疗耐药中的血管共选择
Front Oncol. 2023 Dec 11;13:1323350. doi: 10.3389/fonc.2023.1323350. eCollection 2023.
本文引用的文献
1
Mechanisms of resistance to anti-angiogenic treatments.抗血管生成治疗的耐药机制。
Cancer Drug Resist. 2019 Sep 19;2(3):595-607. doi: 10.20517/cdr.2019.39. eCollection 2019.
2
Hallmarks of Cancer: New Dimensions.癌症的特征：新视角。
Cancer Discov. 2022 Jan;12(1):31-46. doi: 10.1158/2159-8290.CD-21-1059.
3
Neutrophils expressing lysyl oxidase-like 4 protein are present in colorectal cancer liver metastases resistant to anti-angiogenic therapy.表达赖氨酰氧化酶样蛋白 4 的中性粒细胞存在于对抗血管生成治疗有抵抗的结直肠癌肝转移中。
J Pathol. 2020 Jun;251(2):213-223. doi: 10.1002/path.5449. Epub 2020 May 18.
4
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment.免疫检查点阻断与抗血管生成在癌症治疗中的协同作用。
Mol Cancer. 2019 Mar 30;18(1):60. doi: 10.1186/s12943-019-0974-6.
5
Vessel co-option in cancer.血管生成拟态在癌症中的作用
Nat Rev Clin Oncol. 2019 Aug;16(8):469-493. doi: 10.1038/s41571-019-0181-9.
6
Non-angiogenic tumours and their influence on cancer biology.非血管性肿瘤及其对癌症生物学的影响。
Nat Rev Cancer. 2018 May;18(5):323-336. doi: 10.1038/nrc.2018.14. Epub 2018 Mar 9.
7
Roles of RUNX in Hypoxia-Induced Responses and Angiogenesis.RUNX在缺氧诱导反应和血管生成中的作用。
Adv Exp Med Biol. 2017;962:449-469. doi: 10.1007/978-981-10-3233-2_27.
8
Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma.肝癌中肝血管的选择利用而非血管生成驱动了索拉非尼获得性耐药
J Natl Cancer Inst. 2016 Apr 8;108(8). doi: 10.1093/jnci/djw030. Print 2016 Aug.
9
VEGF targets the tumour cell.VEGF 靶向肿瘤细胞。
Nat Rev Cancer. 2013 Dec;13(12):871-82. doi: 10.1038/nrc3627.
10
VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex.VEGF 通过 MET/VEGFR2 复合物抑制肿瘤细胞侵袭和间质转化。
Cancer Cell. 2012 Jul 10;22(1):21-35. doi: 10.1016/j.ccr.2012.05.037.
Zotero 插件